Literature DB >> 18619637

Development and pathogenic evaluation of recombinant herpes simplex virus type 1 expressing two fluorescent reporter genes from different lytic promoters.

Srividya Ramachandran1, Jared E Knickelbein, Christina Ferko, Robert L Hendricks, Paul R Kinchington.   

Abstract

To develop means to explore viral gene expression in ganglia without laborious histological sectioning and staining, we created a two color fluorescent recombinant HSV-1, in which enhanced green fluorescent protein (EGFP) and red fluorescent protein (RFP) are expressed from the glycoprotein B (gB) and glycoprotein C (gC) promoters respectively. We show that this virus retained growth and pathogenic capacity both in vitro and in vivo compared to wild type HSV-1; established latent infections with similar genome copy number in trigeminal ganglia (TG); induced a similar HSV-specific CD8(+) T cell infiltrate; did not induce CD8(+) T cells reactive to EGFP or RFP; and reactivated from latency with normal kinetics in ex vivo TG cultures. Fluorescent EGFP expression in plaques surrounding neurons preceded RFP expression and provided highly sensitive detection of reactivation and different stages of infection in ex vivo TG cultures. Expression of both EGFP and RFP in neurons was readily detectable in whole mounts of TG excised during acute infection and following in vivo sodium butyrate-induced reactivation from latency. This virus constitutes a useful reagent for monitoring lytic viral promoter activity in sensory neurons in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18619637      PMCID: PMC2613845          DOI: 10.1016/j.virol.2008.05.034

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  32 in total

1.  Pathways of viral gene expression during acute neuronal infection with HSV-1.

Authors:  T P Margolis; F Sedarati; A T Dobson; L T Feldman; J G Stevens
Journal:  Virology       Date:  1992-07       Impact factor: 3.616

2.  Endogenously produced interferon alpha protects mice from herpes simplex virus type 1 corneal disease.

Authors:  R L Hendricks; P C Weber; J L Taylor; A Koumbis; T M Tumpey; J C Glorioso
Journal:  J Gen Virol       Date:  1991-07       Impact factor: 3.891

3.  Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice.

Authors:  Gary D Luker; J Patrick Bardill; Julie L Prior; Christina M Pica; David Piwnica-Worms; David A Leib
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. IV. Recognition and activation by cloned glycoproteins gB and gD.

Authors:  J M Zarling; P A Moran; R L Burke; C Pachl; P W Berman; L A Lasky
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

5.  Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins.

Authors:  R W Honess; B Roizman
Journal:  J Virol       Date:  1974-07       Impact factor: 5.103

6.  Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice.

Authors:  Lawrence T Feldman; Aaron R Ellison; Cynthia C Voytek; Li Yang; Philip Krause; Todd P Margolis
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

7.  The early expression of glycoprotein B from herpes simplex virus can be detected by antigen-specific CD8+ T cells.

Authors:  Scott N Mueller; Claerwen M Jones; Weisan Chen; Yoshihiro Kawaoka; Maria R Castrucci; William R Heath; Francis R Carbone
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

8.  Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response.

Authors:  Diethilde Theil; Tobias Derfuss; Igor Paripovic; Simone Herberger; Edgar Meinl; Olaf Schueler; Michael Strupp; Viktor Arbusow; Thomas Brandt
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

9.  Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia.

Authors:  Kamal M Khanna; Robert H Bonneau; Paul R Kinchington; Robert L Hendricks
Journal:  Immunity       Date:  2003-05       Impact factor: 31.745

10.  Herpes simplex virus type 1 evades the effects of antibody and complement in vivo.

Authors:  John M Lubinski; Ming Jiang; Lauren Hook; Yueh Chang; Chad Sarver; Dimitrios Mastellos; John D Lambris; Gary H Cohen; Roselyn J Eisenberg; Harvey M Friedman
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more
  17 in total

1.  Delaying the expression of herpes simplex virus type 1 glycoprotein B (gB) to a true late gene alters neurovirulence and inhibits the gB-CD8+ T-cell response in the trigeminal ganglion.

Authors:  Srividya Ramachandran; Katherine A Davoli; Michael B Yee; Robert L Hendricks; Paul R Kinchington
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

2.  Broad-spectrum non-nucleoside inhibitors of human herpesviruses.

Authors:  Lora McClain; Yun Zhi; Hoyee Cheng; Ayantika Ghosh; Paolo Piazza; Michael B Yee; Santosh Kumar; Jadranka Milosevic; David C Bloom; Ravit Arav-Boger; Paul R Kinchington; Robert Yolken; Vishwajit Nimgaonkar; Leonardo D'Aiuto
Journal:  Antiviral Res       Date:  2015-06-12       Impact factor: 5.970

3.  The alphaherpesvirus US3/ORF66 protein kinases direct phosphorylation of the nuclear matrix protein matrin 3.

Authors:  Angela Erazo; Michael B Yee; Bruce W Banfield; Paul R Kinchington
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

4.  A5-positive primary sensory neurons are nonpermissive for productive infection with herpes simplex virus 1 in vitro.

Authors:  Andrea S Bertke; Sophia M Swanson; Jenny Chen; Yumi Imai; Paul R Kinchington; Todd P Margolis
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

5.  Mouse Mx1 Inhibits Herpes Simplex Virus Type 1 Genomic Replication and Late Gene Expression In Vitro and Prevents Lesion Formation in the Mouse Zosteriform Model.

Authors:  Melkamu B Tessema; Rubaiyea Farrukee; Christopher E Andoniou; Mariapia A Degli-Esposti; Clare V Oates; James B Barnes; Linda M Wakim; Andrew G Brooks; Sarah L Londrigan; Patrick C Reading
Journal:  J Virol       Date:  2022-05-31       Impact factor: 6.549

6.  Viral forensic genomics reveals the relatedness of classic herpes simplex virus strains KOS, KOS63, and KOS79.

Authors:  Christopher D Bowen; Daniel W Renner; Jacob T Shreve; Yolanda Tafuri; Kimberly M Payne; Richard D Dix; Paul R Kinchington; Derek Gatherer; Moriah L Szpara
Journal:  Virology       Date:  2016-03-21       Impact factor: 3.616

7.  iPSC Neuronal Assay Identifies Amaryllidaceae Pharmacophore with Multiple Effects against Herpesvirus Infections.

Authors:  James McNulty; Leonardo D'Aiuto; Yun Zhi; Lora McClain; Carlos Zepeda-Velázquez; Spencer Ler; Hilary A Jenkins; Michael B Yee; Paolo Piazza; Robert H Yolken; Paul R Kinchington; Vishwajit L Nimgaonkar
Journal:  ACS Med Chem Lett       Date:  2015-11-19       Impact factor: 4.345

8.  Rapid genome assembly and comparison decode intrastrain variation in human alphaherpesviruses.

Authors:  Lance R Parsons; Yolanda R Tafuri; Jacob T Shreve; Christopher D Bowen; Mackenzie M Shipley; L W Enquist; Moriah L Szpara
Journal:  MBio       Date:  2015-03-31       Impact factor: 7.867

9.  Herpes Simplex Virus 1-Specific CD8+ T Cell Priming and Latent Ganglionic Retention Are Shaped by Viral Epitope Promoter Kinetics.

Authors:  Benjamin R Treat; Sarah M Bidula; Anthony J St Leger; Robert L Hendricks; Paul R Kinchington
Journal:  J Virol       Date:  2020-02-14       Impact factor: 6.549

10.  Persistent infection by HSV-1 is associated with changes in functional architecture of iPSC-derived neurons and brain activation patterns underlying working memory performance.

Authors:  Leonardo D'Aiuto; Konasale M Prasad; Catherine H Upton; Luigi Viggiano; Jadranka Milosevic; Giorgio Raimondi; Lora McClain; Kodavali Chowdari; Jay Tischfield; Michael Sheldon; Jennifer C Moore; Robert H Yolken; Paul R Kinchington; Vishwajit L Nimgaonkar
Journal:  Schizophr Bull       Date:  2014-03-12       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.